This medical device keeps the coronary artery open while controlling the dose of medication and preventing blockage and excessive scaring. Coating the stent in biodegradable polymer containing the exact dose of medication ensures its total release and avoids potentially toxic drug retention. With heart disease and blocked coronary arteries among the major killers in the western world, this project hopes to pave the way for more precise drug delivery and increase success levels in heart surgery.
Ensuring blood supply to the heart, through the coronary artery, is essential to keep it working. However, the coronary artery is particularly prone to narrowing, causing a restricted blood flow and leading to angina or heart attacks. By inserting a wire mesh tube collapsed to a narrow diameter (the stent) into the narrow part of the artery, and inflating a balloon catheter inside, the artery is successfully held open. This procedure often causes damage to the artery wall; scar tissue forms around the stent and blocks the artery. The current technology consists in coating the stent with a biodegradable polymer bound with a drug to control this unwanted cell growth.
Less drug needed
The major problem with current drug eluting stents is that 85% of the drug, which is very toxic, remains in the coronary vessel for the rest of the patient’s life because it is bound in the polymer. To remedy this problem, the participants in the project developed a bio-absorbable polymer which is completely absorbed after about three weeks. This means it is possible to use a much smaller dose of drug, allowing for complete assimilation and leaving none unused in the stent. Blue Medical, a project participant from the Netherlands, has developed the optimum biopolymer and two drugs which will regulate excessive cell growth with much lower toxicity than is currently needed. Extensive testing has led to creating a uniform, reproducible and accurate biopolymer coating for the metal stent.
Blue Medical Devices focused on the drugs development, their interaction with the polymer and designing and validating the dosage as well as the elution rates and determining the effect of bio-absorption. Their partner, Creganna Medical Devices from Ireland, developed the process of applying the biodegradable polymer to the metal surface of the stent, with or without a drug component.
Both partners foresee a strong future for the product, which should be available in mid-2007. The projected market could reach 30% of the total stent market outside the US; worth €800m. Blue Medical has increased its workforce from 30 to 50 in two years and expects to employ 150 people by 2008. “As well as substantial financial benefit, participating in a EUREKA project has given the project a much higher profile and status, enabling strong international working relationships to be developed,” believes Ronald Horvers, project coordinator at Blue Medical Devices.
Sally Horspool | alfa
New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia
New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences